Agios Pharmaceuticals gained priority review status for its mitapivat application from the FDA.
3 reports, 3 independent
Updated Jul 30
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Agios Pharmaceuticals gained priority review status for its mitapivat application from the FDA.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Agios Pharmaceuticals
a public American pharmaceutical company
- FDA
Related events
- The FDA recommended advancement for a new drug application submitted by a company.
- GSK is seeking priority review for its Jemperli application, and the FDA set the PDUFA action date.
- A product was launched in the U.S. market following FDA involvement.
- The FDA is currently reviewing new drug applications for market entry.
- FDA clearance drives market expansion and coverage for NeurAxis, Inc.